A novel aromatic mutagen, 5-amino-6-hydroxy-8H-benzo[6,7]azepino[5,4,3-de]quinolin-7-one (ABAQ), induces colonic preneoplastic lesions in mice  by Kochi, Takahiro et al.
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The  benzoazepinoqunolinone  derivative,  5-amino-6-hydroxy-8H-benzo[6,7]azepino-
[5,4,3-de]quinolin-7-one  (ABAQ),  which  is  produced  in  a  mixture  of glucose  and  tryp-
tophan  incubated  at 37 ◦C  under  physiological  conditions  in the presence  or absence  of
hydroxyl  radicals  caused  by the Fenton  reaction,  is  a novel  aromatic  mutagen.  In the  current
study,  we  determined  the  tumor-initiating  potency  of ABAQ  using  an  inﬂammation-relate,
two-stage  mouse  colon  carcinogenesis  model.  Male  Crj:  CD-1  (ICR)  mice  were  treated
with the single  intragastric  administration  (100  or 200  mg/kg  body  weight)  of ABAQ
followed  by  subsequent  1-week  oral  exposure  to  2%  dextran  sodium  sulfate (DSS) in
drinking  water.  The  ABAQ  treatment  alone  resulted  in  high-grade  dysplasia,  which  is  a
precursor  to colorectal  cancer,  in the  colon.  Following  the  administration  of  DSS after
ABAQ  treatment,  the  incidence  and  frequency  of high-grade  dysplastic  lesions  increased;
the values  were  highest  in  the  mice  treated  with  200  mg/kg  body  weight  of  ABAQ  followed
by DSS.  The  lesions  expressing  -catenin  in  their  nuclei  and  cytoplasm  exhibited  highextran  sodium sulfate
nitiation
ice
proliferation  activity  without  the  expression  of  programmed  cell  death  4.  These  ﬁndings
indicate  that ABAQ  has  a tumor-initiating  activity  in  the  mouse  colon,  with  or  without
inﬂammation,  although  the potential  pro-inﬂammatory  effect  of  high  doses  of  ABAC
should  be  investigated.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  underthe CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).Abbreviations: ABAQ, 5-amino-6-hydroxy-8H-benzo[6,7]azepino[5,4,3-de]qu
eterocyclic  amine; H&E, hematoxylin and eosin; i.g., intragastric; MeIQx, 2-a
ydrocarbons;  PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
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Fig. 1. (a) Chemical structure of ABAQ (ABAQ, C16H11N3O2, MW = 277.28).
(b) A high-grade colonic dysplasia on H&E-stained section from a mouse
in  group 2 (200 ppm ABAQ + DSS). Note: Nuclear atypia in the crypts and
Paneth’s granules (red in color) in the cytoplasm of some dysplastic crypt
cells. H&E stain; bar, 50 m.  (c) Many nuclei in the high-grade dysplasia
in a serial section from (b) are positive for MCM2.  MCM2  immunohis-
tochemistry; bar, 50 m. (d) Most nuclei in the high-grade dysplasia in
a  serial section from (b) are negative for PDCD4, whereas the nuclei in
the surrounding normal crypts are positive for PDCD4. PDCD4 immuno-
histochemistry; bar, 50 m.  (e) The cytoplasmic expression of -catenin
is present in the high-grade dysplasia lesion developed in the colon of a
mouse from group 2 (200 ppm ABAQ + DSS). Some nuclei are weakly pos-70 T. Kochi et al. / Toxico
1. Introduction
Human people are continuously exogenously exposed
to  a variety of chemicals that have been shown to have
mutagenic or carcinogenic properties in experimental
systems [1]. Cooking meat and ﬁsh at a high temper-
ature (above 180 ◦C) forms mutagenic and carcinogenic
heterocyclic amines (HCAs) and polycyclic aromatic hydro-
carbons  (PAHs). HCAs are formed by the pyrolysis of
creati(ni)ne with sugars with speciﬁc amino acids. Since
a  high temperature is needed, only fried, broiled or
barbecued meat contains a signiﬁcant amount of HCAs
[2].  Experimental studies of HCAs began with Dr. Sug-
imura’s discovery that cooked meat and ﬁsh contain potent
mutagens [2]. Some HCAs were later shown to be com-
plete  carcinogens that induce liver, colon, mammary and
prostate  tumors in rodents and monkeys [2,3]. Certain
HCAs are consistently identiﬁed in well-done meat prod-
ucts  consumed in the North American diet. Although a
causal  link has not been fully established, a majority of
epidemiology studies have linked the consumption of well-
done  meat products to cancer of the colon and breast.
Several HCAs thus represent an important class of car-
cinogens in foods and have been classiﬁed as “possibly
carcinogenic to humans (Group 2B)” or “probably carcino-
genic  to humans (Group 2A)” by the IARC [4] and “Group
2:  reasonably anticipated to be human carcinogens (R)” by
the  NTP [5]. Similar to most other chemical carcinogens,
HCAs must be metabolized by CYP1A2 or CYP1B1 to chem-
ically  reactive electrophiles prior to reacting with DNA in
order  to exert their carcinogenic potency in both rats and
humans  [2].
Certain  compounds that are mutagenic and car-
cinogenic in cooked foods are formed by the Maillard
reaction of reducing sugars and amino acids. Indeed,
2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)
and  2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP) are mutagenic and carcinogenic HCAs formed
through the Maillard reaction in meat and ﬁsh cooked at a
high  temperature [2]. These compounds are suggested to
be  formed by the reaction of creatine with Maillard reac-
tion  products from glucose and amino acids by heating at
a  high temperature of 128 ◦C [2,3,6]. The Maillard reaction
can  also occur at physiological temperatures. In a series of
our  study performed to clarify the formation of mutagens
during the Maillard reaction in glucose and amino acids, we
recently  identiﬁed a novel aromatic mutagen, 5-amino-6-
hydroxy-8H-benzo[6,7]azepino[5,4,3-de]quinolin-7-one
(ABAQ, C16H11N3O2, MW = 277.28, Fig. 1a), formed in the
mixture of glucose and tryptophan incubated at 37 ◦C and
a  pH of 7.4 in the presence or absence of hydroxyl radicals
produced by the Fenton reaction [7]. ABAQ exhibits a
strong  mutagenic activity toward S. typhimurium TA98
and  YG1024 with S9 mix  [7]. The mutagenic potency of
ABAQ  is comparable to that of PhIP [7]. ABAQ also revealed
mutagenicity in the liver of gpt delta transgenic mice [8].
In  order to understand the effects of ABAQ on human
health, it is important to elucidate its tumor-initiating abil-
ity  in rodents. The current study thus aimed to determine
whether the novel mutagen ABAQ possesses a tumor-
initiation activity in the colon in in vivo experiment initive  for -catenin. -Catenin immunohistochemistry; bar, 50 m.  (For
interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of the article.)
mice. We used an experimental model employing a colitis-
inducing agent, dextran sodium sulfate (DSS), which has a
powerful  tumor-promotion activity [9], since the tumor-
initiation activity of PhIP [10] and aminophenylnorharman
[11] can be detected within a short-term period in this
model. The single administration with ABAQ in two doses
via  gavage resulted in development of high-grade dyspla-
sia  in the inﬂamed colon induced by DSS in male mice. The
immunohistochemical analysis revealed the lesions with a
high  proliferative activity and cytoplasmic and/or nuclear
expression of -catenin to be negative for programmed cell
death  4 (PDCD4), suggesting the tumor-initiation ability of
ABAQ.
2.  Materials and methods
2.1.  Animals, chemicals and diet
Male Crlj: CD-1 (ICR) mice (Charles River Japan, Tokyo,
Japan) 5 weeks of age were used. The mice were maintained
at  Gifu University Animal Facility according to the Institu-
tional  Animal Care Guidelines. All animals were housed in
plastic  cages (3 or 4 mice/cage) with free access to drink-
ing  water and a pelleted basal diet, CRF-1 (Oriental Yeast,
Tokyo,  Japan), under controlled conditions of humidity
(50 ± 10%), light (12/12-h light/dark cycle) and tempera-
ture (23 ± 2 ◦C). After seven days of quarantine, they were
randomized according to body weight into experimental
and control groups. ABAQ was synthesized as previously
described [7]; its purity was conﬁrmed to be > 99% by
HPLC.  DSS with a molecular weight of 36,000–50,000 (Cat
No.  160110) was  purchased from MP  Biochemicals, LLC
(Aurora,  OH, USA).
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Table 1
Body,  liver and relative liver weights and colon lengths in all groups.
Group no. Treatment (no. of mice
examined)
Body weight (g) Liver weights (g) Relative liver weight
(g/100  g body weight)
Colon length (cm)
1 ABAQ a (100 mg/kg bw) → 2% DSS (15) 49.9 ± 7.29 b 2.5 ± 0.53 c 5.0 ± 0.48 d 16.5 ± 1.30 c
2 ABAQ (200 mg/kg bw) → 2% DSS (15) 44.8 ± 9.46 2.2 ± 0.56 4.8 ± 0.37 c 15.6 ± 1.31
3  ABAQ (200 mg/kg bw) (5) 42.0 ± 3.46 1.7 ± 0.23 e 4.1 ± 0.29 14.3 ± 0.42 e
4 Solvent → 2% DSS (5) 47.6 ± 1.62 2.1 ± 0.13 4.5 ± 0.35 15.9 ± 1.33
5  None (8) 51.6 ± 7.95 2.5 ± 0.45 4.8 ± 0.58 16.4 ± 1.21
a ABAQ, 5-amino-6-hydroxy-8H-benzo[6,7]azepino[5,4,3-de]quinolin-7-one;  DSS, dextran sodium sulfate.
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orectum, in all groups. Fatty changes were observed in the
liver  of two mice (13%) in group 1, but not in other groups.
As  indicated in Table 2, colonic dysplasia (high-grade,b Mean ± SD.
,d Signiﬁcantly different from group 3 (c p < 0.05 and d p < 0.01) according
e Signiﬁcantly different from group 5 (p < 0.05).
.2. Experimental procedure for evaluating the
umor-initiating activity
The  present study was approved by the Experimental
nimal Research Committee of Gifu University. A total of
8  male ICR mice were divided into ﬁve experimental and
olvent  control groups. Groups 1 through 3 were treated
ith  the single intragastric (i.g.) intubation of ABAQ at
 dose of 100 or 200 mg/kg body weight. Starting one
eek after the ABAQ treatment, the animals in groups
 (n = 15) and 2 (n = 15) were given 2% (w/v) DSS in
rinking water for seven days, followed by no further
reatments for 14 weeks. Groups 3 (n = 5) and 4 (n = 5)
ere  given ABAQ (200 mg/kg body weight) alone and
%  DSS alone, respectively. Group 5 (n = 8) was  given
olvent (physiological saline) alone and served as an
ntreated control group. All animals were sacriﬁced via
O2 asphyxiation at week 16. The colons were ﬂushed with
aline,  excised, measured for length (from the ileocecal
unction to the anal verge), cut open longitudinally along
he  main axis and washed with saline. After carefully
acroscopically inspecting the colons, the tissues were
ut  and ﬁxed in 10% buffered formalin for at least 24 h.
 histological examination was performed on parafﬁn-
mbedded sections following hematoxylin and eosin
H&E) staining. The presence or absence of mucosal ulcer-
tion,  dysplasia and colonic neoplasms was examined
ccording to our previous report [9]. A histopatho-
ogical examination was also performed for other
rgans.
.3. Immunohistochemistry of minichromosome
aintenance protein 2 (MCM2), ˇ-catenin and
rogrammed cell death 4 (PDCD4)
We used parafﬁn-embedded sections of the colons of
he  mice in all groups for the immunohistochemical analy-
is.  Serial histological sections (4 m thickness) were made
rom  each parafﬁn wax block. Immunohistochemical stain-
ng  was performed automatically (Ventana Benchmark
Tsystem; Ventana, Touchstone, Arizona, USA), according
o  the manufacturer’s instructions. The primary antibod-
es  were anti-MCM2 rabbit monoclonal antibody (no. 3619,
nti-MCM2 (D7611)XP, 1:400 dilution; Cell Signaling Tech-
ology,  Inc., Danvers, MA,  USA), anti--catenin rabbit
olyclonal antibody (#9661, 1:200 dilution; Cell Signaling
echnology) and anti-PCDC4 rabbit polyclonal antibodye-way ANOVA and the Tukey–Kramer Multiple Comparison test.
(ab51495, 1:500 dilution; Abcam, Inc. Cambridge, MA,
USA).  In each case, the positive and negative controls were
run  concurrently. As the ﬁnal step, the sections were lightly
counterstained with Mayer’s hematoxylin (Merck, Tokyo,
Japan).
Immunoreactivity for antibodies against MCM2,  PDCD4
and  -catenin was  assessed in the lesions (high-grade
dysplasia) that developed in groups 1 through 3 using a
microscope (Olympus BX41, Olympus Optical Co., Tokyo,
Japan).  The intensity and localization of the immunoreac-
tivity against the primary antibodies were determined by a
pathologist  (T.T.) who was unaware of the treatment group
to  which the slide belonged.
2.4.  Statistical analysis
All  measurements were compared using a one-way
ANOVA with either Tukey’s correction or Fisher’s exact
probability test (GraphPad Instat version 3.05, GraphPad
Software, San Diego, CA), with a value of p < 0.05 as the
criterion for signiﬁcance.
3.  Results
3.1. General observations
As  listed in Table 1, the mean liver (p < 0.05) and relative
liver weights (p < 0.01), and mean colon length (p < 0.05)
in  group 1 (100 mg/kg ABAQ + 2% DSS) were signiﬁcantly
larger than those observed in group 3 (200 mg/kg ABAQ
alone). The mean liver weight and colon length of group
3  were signiﬁcantly lower than that of group 5 (solvent
control) (p < 0.05 for each comparison).
3.2.  Pathological ﬁndings of the liver and colorectum of
mice  treated with ABAQ and/or DSS
There were no tumors in any organs, including the col-Fig. 1b) developed in groups 1 through 3. DSS exposure
increased the multiplicity of high-grade dysplasia induced
by  ABAQ. There were no dysplastic lesions in the mice in
groups  4 and 5.
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Table 2
Incidence and multiplicity of colonic lesions in the mice in each group.
Group no. Treatment (no. of mice examined) Mucosal ulcer High-grade dysplasia
1 ABAQ a (100 mg/kg bw) → 2% DSS (15) 10/15 (67%) 1.40 ± 1.18 b 4/15 (27%) c, d 0.53 ± 1.13
2  ABAQ (200 mg/kg bw) → 2% DSS (15) 11/15 (73%) 1.27 ± 1.16 10/15 (67%) e 1.60 ± 1.50
3 ABAQ (200 mg/kg bw) (5) 0/5 (0%) 0 1/5 (20%) 0.20 ± 0.45
4  Solvent → 2% DSS (5) 5/5 (100%) 1.80 ± 0.84 f 0/5 (0%) 0
5 None (8) 0/8  (0%) 0 0/8 (0%) 0
a ABAQ, 5-amino-6-hydroxy-8H-benzo[6,7]azepino[5,4,3-de]quinolin-7-one;  DSS, dextran sodium sulfate.
d group
 ANOVAb Mean ± SD.
c,d,e Signiﬁcantly different from group 2 (c p < 0.05), group 3 (d p < 0.05) an
f Signiﬁcantly different from group 5 (p < 0.05) according to a one-way
3.3. Immunohistochemical expression of MCM2,
ˇ-catenin, and PDCD4 in the high-grade dysplasia lesions
The  nuclei in the high-grade dysplasia lesions were pos-
itive  for MCM2  (Fig. 1c), reﬂecting a high proliferation
activity, and negative for PDCD4 (Fig. 1d). A cytoplasmic
and nuclear expression of -catenin was observed in the
high-grade dysplasia lesions (Fig. 1e).
4. Discussion
In this study, we conﬁrmed the tumor-initiating ability
of  ABAQ in an inﬂammation-associated, two-stage mouse
carcinogenesis model. Importantly, ABAQ treatment alone
produced  lesions exhibiting high-grade dysplasia lesions
that  are preneoplastic for colorectal cancer, although
the incidence and multiplicity were low and statistically
insigniﬁcant from group 5 (untreated control). One week
of  exposure to DSS after the single i.g. administration of
ABAQ  increased the incidence and number of high-grade
dysplasia lesions in the colorectum. The dysplasia-inducing
potency was considered to be dose-dependent, although
only two doses of ABAQ were applied in this study.
In this study, dosing of ABAQ (100 mg/kg) followed by
DSS  (group 1) increased the liver weight, while 200 mg/kg
of  ABAQ (group 2) did not. However, both doses of ABAQ
increased the relative liver weight. Fatty degeneration
observed in the liver of a few mice of group 1 may  be related
to  these changes. As to the colon length, the treatment
of ABAQ alone (group 3) shortened the colon, suggesting
pro-inﬂammatory action of ABAQ, but the colon lengths of
groups  1 and 2 were increased when given DSS. In order
to  proof the dose dependency and discard the possible
pro-inﬂammatory effect at higher doses of ABAQ, which
might contribute to the tumor development, it would be
interesting to use three or four different doses (from 50 to
200  mg/kg, for instance). Such an experiment is planned in
our  laboratory.
The  Maillard reaction in vivo is involved in aging [12] and
a  variety of chronic diseases, such as diabetes and related
retinopathy and nephropathy [13]. Pyrraline is formed as
an  advanced glycation end product in the Maillard reac-
tion  between glucose and the -amino group of lysine
under physiological conditions [14]. The serum [15] and
urine  [16] concentrations of pyrraline are known to be
increased in diabetic patients, and pyrraline is detected in
individuals  with diabetic glomerulosclerosis [17]. Epidemi-
ological  [18,19] and experimental investigations [20,21] 4 (e p < 0.05) according to the Fisher’s exact probability test.
 and the Tukey–Kramer Multiple Comparison test.
have  indicated a positive association between diabetes and
cancer  development in several tissues, including the col-
orectum, suggesting that certain chemicals formed by the
Maillard  reaction in the body increase the risk of cancer
in  patients with diabetes. However, little is known about
mutagens formed through the Maillard reaction in vivo.
In  this study, we  observed high-grade dysplasia in the
colorectum of the mice treated with ABAQ alone and
ABAQ followed by DSS exposure. Although no colorectal
neoplasms developed, these ﬁndings are of importance
since high-grade dysplasia is known to be a precursor
lesion of inﬂammatory conditions in the colon, such as
inﬂammatory bowel disease (IBD) [22]. In the fact, the
high-grade dysplasia observed in this study increased the
degree  of proliferation, as estimated on MCM2  immuno-
histochemistry, and altered the expression of -catenin in
the  cytoplasm and nuclei. More importantly, almost null
expression of PDCD4 was observed in the high-grade dys-
plasia  lesions. This ﬁnding is in accordance with the results
showing a negative expression of PDCD4 in patients with
sporadic  colorectal cancer [23,24], IBD-related colorectal
cancer [22,25] and dysplasia in IBD [22,25].
In conclusion, the results of the current study indicate
the potential tumor-initiating activity of ABAQ in the colon,
with  and without inﬂammation. Although the ABAQ level
has  not been determined in healthy subjects, ABAQ is a
potential novel endogenous mutagen and tumor-initiating
compound, as shown in this study and a previous investiga-
tion  [7]. Since the mutagenic activity of ABAQ is comparable
to  that of PhIP [7], additional studies of the carcinogenicity
of ABAQ in the colon and other tissues are required. Our
ﬁndings provide a scientiﬁc basis for further research on
the  involvement of ABAQ in human health.
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